David M Simpson

Address:

2260 E Lauri Kay Dr, Salt Lake Cty, UT 84124

VIN:

4T1FA38P97U120209

Make:

TOYOTA

Model:

CAMRY SOLARA

Year:

2007

US Patent:

8637651, Jan 28, 2014

Filed:

Mar 15, 2010

Appl. No.:

12/724403

Inventors:

Kirk E. Apt - Ellicott City MD, US
James Casey Lippmeier - Columbia MD, US
David Simpson - Boulder CO, US
Jun Wang - Cooksville MD, US
James P. Wynn - Columbia MD, US
Ross Zirkle - Mt. Airy MD, US

Assignee:

DSM IP Assets B.V. - Te Heerlen

International Classification:

C07H 21/04
C12P 21/02

US Classification:

536 231, 435 691

Abstract:

The present invention relates to recombinant cells and microorganisms of the phylum Labyrinthulomycota and their use in heterologous protein production. Novel promoter, terminator, and signal sequences for efficient production and, optionally, secretion of polypeptides from recombinant host cells and microorganisms are also encompassed by the present invention.

US Patent:

20030096765, May 22, 2003

Filed:

Jul 25, 2002

Appl. No.:

10/205115

Inventors:

John Kenten - Gaithersburg MD, US
Reid Von Borstel - Potomac MD, US
Jan Casadei - Bethesda MD, US
Balreddy Kamireddy - Rockville MD, US
Mark Martin - Germantown MD, US
Richard Massey - Rockville MD, US
Andrew Napper - Natick MA, US
David Simpson - Adelphi MD, US
Rodger Smith - Jefferson MD, US
Richard Titmas - Rockville MD, US
Richard Williams - Potomac MD, US

Assignee:

Igen, Inc.

International Classification:

A61K031/704
A61K031/66
C07H015/24
C07F009/02
A61K031/235

US Classification:

514/034000, 514/120000, 514/110000, 514/538000, 514/544000, 536/006100, 558/166000, 558/179000, 560/019000, 560/103000

Abstract:

Disclosed and claimed are prodrugs activated by catalytic proteins, such as enzymes and catalytic antibodies. The invention comprehends such prodrugs, as well as haptens, to elicit catalytic antibodies to activate the prodrugs. The prodrugs are useful as cytotoxic chemotherapeutic agents; e.g., as antitumor agents.

US Patent:

20050123533, Jun 9, 2005

Filed:

Nov 3, 2003

Appl. No.:

10/699966

Inventors:

John Kenten - Gaithersburg MD, US
Reid Borstel - Potomac MD, US
Jan Casadei - Bethesda MD, US
Balreddy Kamireddy - Rockville MD, US
Mark Martin - Germantown MD, US
Richard Massey - Rockville MD, US
Andrew Napper - Natick MA, US
David Simpson - Adelphi MD, US
Rodger Smith - Jefferson MD, US
Richard Titmas - Rockville MD, US
Richard Williams - Potomac MD, US

International Classification:

A61K039/395
C07H015/24
C07K016/18

US Classification:

424130100, 530388100, 540200000, 536006400, 560040000, 530395000, 530403000

Abstract:

Disclosed and claimed are prodrugs activated by catalytic proteins, such as enzymes and catalytic antibodies. The invention comprehends such prodrugs, as well as haptens, to elicit catalytic antibodies to activate the prodrugs. The prodrugs are useful as cytotoxic chemotherapeutic agents; e.g., as antitumor agents.

US Patent:

20100266564, Oct 21, 2010

Filed:

Mar 19, 2010

Appl. No.:

12/727851

Inventors:

Kirk E. Apt - Ellicott City MD, US
Leslie Richter - Broomfield CO, US
David Simpson - Boulder CO, US
Ross Zirkle - Mt. Airy MD, US

International Classification:

C12N 15/52
C12N 15/63
C12N 5/10
C12N 1/00
C12P 7/64
C12N 9/00
A61K 38/43
A61K 48/00
A61P 3/00

US Classification:

424 941, 536 232, 4353201, 435419, 435243, 435325, 435134, 435183, 514 44 R

Abstract:

The present invention is directed to isolated nucleic acid molecules and polypeptides of thraustochytrid polyunsaturated fatty acid (PUFA) synthases involved in the production of PUFAs, including PUFAs enriched in docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), or a combination thereof. The present invention is directed to vectors and host cells comprising the nucleic acid molecules, polypeptides encoded by the nucleic acid molecules, compositions comprising the nucleic acid molecules or polypeptides, and methods of making and uses thereof.

US Patent:

61210072, Sep 19, 2000

Filed:

Nov 13, 1996

Appl. No.:

8/747654

Inventors:

Mark T. Martin - Germantown MD
Rodger G. Smith - Jefferson MD
Michael J. Darsley - Rockville MD
David M. Simpson - Adelphi MD
Gary F. Blackburn - Gaithersburg MD

Assignee:

IGEN International Inc. - Gaithersburg MD

International Classification:

C12Q 125

US Classification:

435 76

Abstract:

Disclosed and claimed are methods for selecting a recombinant virus, phage or cell expressing a catalytic antibody or catalytic portion thereof, or for selecting catalytic activity by a moiety. The method employs reaction-based selection for catalytic activity. The method can also be used to concentrate (increase the proportion of catalytic to non-catalytic moieties) a sample containing a catalytic moiety or viruses, phages or cells expressing a catalytic moiety. The selection or concentrating can be by employing a mechanism-based inhibitor, catalysis-accelerated movement, surface binding, changes in enthalpic component of binding as a function of temperature, or changes in binding by competition, or combinations thereof. The invention also comprehends a method for producing a recombinant virus or a cell-line expressing a catalytic moiety such as a catalytic antibody or catalytic portion thereof; and, this method can include infecting a suitable host with viruses which are screened for the expression. In addition, recombinant viruses and cell-lines so expressing a catalytic moiety such as a catalytic antibody or catalytic portion thereof are also disclosed and claimed.

US Patent:

58916482, Apr 6, 1999

Filed:

Nov 13, 1996

Appl. No.:

8/748415

Inventors:

Mark T. Martin - Germantown MD
Rodger G. Smith - Jefferson MD
Michael J. Darsley - Rockville MD
David M. Simpson - Adelphi MD
Gary F. Blackburn - Gaithersburg MD

Assignee:

Igen, Inc. - Gaithersburg MD

International Classification:

C12Q 125

US Classification:

435 76

Abstract:

Disclosed and claimed are methods for selecting a recombinant virus, phage or cell expressing a catalytic antibody or catalytic portion thereof, or for selecting catalytic activity by a moiety. The method employs reaction-based selection for catalytic activity. The method can also be used to concentrate (increase the proportion of catalytic to non-catalytic moieties) a sample containing a catalytic moiety or viruses, phages or cells expressing a catalytic moiety. The selection or concentrating can be by employing a mechanism-based inhibitor, catalysis-accelerated movement, surface binding, changes in enthalpic component of binding as a function of temperature, or changes in binding by competition, or combinations thereof. The invention also comprehends a method for producing a recombinant virus or a cell-line expressing a catalytic moiety such as a catalytic antibody or catalytic portion thereof; and, this method can include infecting a suitable host with viruses which are screened for the expression. In addition, recombinant viruses and cell-lines so expressing a catalytic moiety such as a catalytic antibody or catalytic portion thereof are also disclosed and claimed.

US Patent:

61772704, Jan 23, 2001

Filed:

Jan 21, 1999

Appl. No.:

9/235353

Inventors:

Mark T. Martin - Germantown MD
Rodger G. Smith - Jefferson MD
Michael J. Darsley - Rockville MD
David M. Simpson - Adelphi MD
Gary F. Blackburn - Gaithersburg MD

Assignee:

IGEN International, Inc. - Gaithersburg MD

International Classification:

C12N 700

US Classification:

4352351

Abstract:

Disclosed and claimed are methods for selecting a recombinant virus, phage or cell expressing a catalytic antibody or catalytic portion thereof, or for selecting catalytic activity by a moiety. The method employs reaction-based selection for catalytic activity. The method can also be used to concentrate (increase the proportion of catalytic to non-catalytic moieties) a sample containing a catalytic moiety or viruses, phages or cells expressing a catalytic moiety. The selection or concentrating can be by employing a mechanism-based inhibitor, catalysis-accelerated movement, surface binding, changes in enthalpic component of binding as a function of temperature, or changes in binding by competition, or combinations thereof. The invention also comprehends a method for producing a recombinant virus or a cell-line expressing a catalytic moiety such as a catalytic antibody or catalytic portion thereof; and, this method can include infecting a suitable host with viruses which are screened for the expression. In addition, recombinant viruses and cell-lines so expressing a catalytic moiety such as a catalytic antibody or catalytic portion thereof are also disclosed and claimed.

US Patent:

55939694, Jan 14, 1997

Filed:

Sep 17, 1993

Appl. No.:

8/123590

Inventors:

Balreddy Kamireddy - Rockville MD
Michael J. Darsley - Rockville MD
David M. Simpson - Adelphi MD
Richard J. Massey - Rockville MD

Assignee:

IGEN Incorporated - Gaithersburg MD

International Classification:

A61K 3170
C07H 302
C07H 304

US Classification:

514 25

Abstract:

A compound of the formula: ##STR1## wherein: each of R. sub. 1, R. sub. 1 ', R. sub. 2 and R. sub. 2 ' independent of each other is a substituted or unsubstituted, branched or linear C. sub. 1-12 alkyl, alkene or alkyne group, R. sub. 3 is OH, OCH. sub. 3, CH. sub. 2 COOH or ##STR2## wherein each of R. sub. 2" and R. sub. 2 '41 independent of each other is a substituted or unsubstituted, branched or linear C. sub. 1-12 alkyl, alkene or alkyne group and: A=NH. sub. 2, X=P(OH), Y=Z=C, B=OCH. sub. 3, or A=OH, X=P(OH), X=Z=C, B (if present)=OCH. sub. 3, or A=OCO(CH. sub. 2). sub. n NH. sub. 2, X=P(OH), Y=Z=C, B=OCH. sub. 3, wherein n=1-10, or A=OH, X=P(OH), Y=Z=C, B=O(CH. sub. 2). sub. n CO. sub. 2 H, wherein n=1-10, or A=OH, X=P(OH), Y=Z=C, B=(CH. sub. 2). sub. n CO. sub. 2 H, wherein n=1-10, or A=NH. sub.